< Back to search
Filter
1

Study of Epcoritamab as a Consolidation Therapy in CLL/SLL

for
CLL/SLL, CLL, SLL, Chronic Lymphocytic Leukemia,
Location: Cincinnati OH
Sponsor: Zulfa Omer

Sex: All

Age: 18+

Code: NCT07108998

Phase2, Recruiting

Mosunetuzumab for CLL MRD Clearance

for
Leukemia, Chronic Lymphocytic Leukemia,
Location: Boston MA
Sponsor: Inhye Ahn

Sex: All

Age: 18+

Code: NCT07052695

Phase1, Phase2, Recruiting

Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL

for
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma,
Location: Cincinnati OH
Sponsor: Zulfa Omer

Sex: All

Age: 18+

Code: NCT07014917

Phase2, Recruiting

Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia

for
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Location: Scarborough ME, Boston MA
Sponsor: Inhye Ahn

Sex: All

Age: 18+

Code: NCT06333262

Phase2, Recruiting

Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial

for
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Location: Newnan GA, Irvine CA, Duarte CA, Long Beach CA
Sponsor: City of Hope Medical Center

Sex: All

Age: 18+

Code: NCT07218510

Phase2, Recruiting

Interested in new leukemia, lymphocytic, chronic, b-cell trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

for
Recurrent Chronic Lymphocytic Leukemia,
Location: Boston MA, Chapel Hill NC, Pittsburgh PA, Columbus OH,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT07061951

Phase2, Recruiting

Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy

for
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukaemia,
Location: Dallas TX, Salt Lake City UT
Sponsor: Bristol-Myers Squibb

Sex: All

Age: 0+

Code: NCT06357754

Recruiting

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

for
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Location: Boston MA, New York NY, Hackensack NJ,
Sponsor: BeOne Medicines

Sex: All

Age: 18+

Code: NCT06973187

Phase3, Recruiting

A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

for
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Location: Durham NC, Kansas City MO, Seattle WA, San Francisco CA
Sponsor: VA Office of Research and Development

Sex: All

Age: 18 - 70+

Code: NCT06520098

Phase2, Recruiting

Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL

for
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (SLL)
Location: Boston MA, New York NY
Sponsor: Massachusetts General Hospital

Sex: All

Age: 18+

Code: NCT06849713

Phase2, Recruiting

Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia

for
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Location: Columbus OH
Sponsor: Jennifer Woyach

Sex: All

Age: 70+

Code: NCT07685717

Phase2, Recruiting

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

for
Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
Location: Portland ME, South Portland ME, Boston MA,
Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 65+

Code: NCT07321652

Phase3, Recruiting

Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

for
Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia (SLL)
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT06967610

Phase2, Recruiting

Global Trial in APG2575 for Patients With CLL/SLL

for
CLL/SLL
Location: Halifax, Boston MA, Greenville NC, Richmond VA,
Sponsor: Ascentage Pharma Group Inc.

Sex: All

Age: 18 - 70+

Code: NCT06104566

Phase3, Recruiting

A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

for
CLL, Chronic Lymphocytic Leukemia
Location: Shirley NY, Westbury NY, New York NY, Greenfield Park,
Sponsor: BeOne Medicines

Sex: All

Age: 18+

Code: NCT06846671

Phase3, Recruiting

Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

for
Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,
Location: Seattle WA
Sponsor: Fred Hutchinson Cancer Center

Sex: All

Age: 18+

Code: NCT07194980

Phase2, Recruiting

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

for
Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
Location: Boston MA, Lake Success NY, New York NY,
Sponsor: Eli Lilly and Company

Sex: All

Age: 18+

Code: NCT06876649

Recruiting

Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

for
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,
Location: Duarte CA
Sponsor: City of Hope Medical Center

Sex: All

Age: 18+

Code: NCT06859008

Phase1, Recruiting

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

for
Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic,
Location: Quebec, Bethesda MD, Richmond VA, West Palm Beach FL,
Sponsor: Loxo Oncology, Inc.

Sex: All

Age: 18+

Code: NCT05254743

Phase3, Recruiting

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

for
Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
Location: Boston MA, Lake Success NY, New York NY,
Sponsor: Eli Lilly and Company

Sex: All

Age: 18+

Code: NCT06876662

Recruiting